Department of Pharmacology, Pondicherry Institute of Medical Sciences, Puducherry, India.
Department of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia.
Eur J Heart Fail. 2022 Sep;24(9):1519-1528. doi: 10.1002/ejhf.2595. Epub 2022 Aug 2.
Contemporary long-term survival following a heart failure (HF) hospitalization is uncertain. We evaluated survival up to 10 years after a HF hospitalization using national data from Australia and New Zealand, identified predictors of survival, and estimated the attributable loss in life expectancy.
Patients hospitalized with a primary diagnosis of HF from 2008-2017 were identified and all-cause mortality assessed by linking with Death Registries. Flexible parametric survival models were used to estimate survival, predictors of survival and loss in life expectancy. A total of 283 048 patients with HF were included (mean age 78.2 ± 12.3 years, 50.8% male). Of these, 48.3% (48.1-48.5) were surviving by 3 years, 34.1% (33.9-34.3) by 5 years and 17.1% (16.8-17.4) by 10 years (median survival 2.8 years). Survival declined with age with 53.4% of patients aged 18-54 years and 6.2% aged ≥85 years alive by 10 years (adjusted hazard ratio [aHR] for mortality 4.84, 95% confidence interval [CI] 4.65-5.04 for ≥85 years vs. 18-54 years) and was worse in male patients (aHR 1.14, 95% CI 1.13-1.15). Prior HF (aHR 1.20, 95% CI 1.18-1.22), valvular and rheumatic heart disease (aHR 1.11, 95% CI 1.10-1.13) and vascular disease (aHR 1.07, 95% CI 1.04-1.09) were cardiovascular comorbidities most strongly associated with long-term death. Non-cardiovascular comorbidities and geriatric syndromes were common and associated with higher mortality. Compared with the general population, HF was associated with a loss of 7.3 years in life expectancy (or 56.6% of the expected life expectancy) and reached 20.5 years for those aged 18-54 years.
Less than one in five patients hospitalized for HF were surviving by 10 years with patients experiencing almost 60% loss in life expectancy compared with the general population, highlighting the considerable persisting societal burden of HF. Concerted multidisciplinary efforts are needed to improve post-hospitalization outcomes of HF.
心力衰竭(HF)住院后的当代长期生存情况尚不确定。我们使用来自澳大利亚和新西兰的全国数据评估了 HF 住院后长达 10 年的生存情况,确定了生存的预测因素,并估计了预期寿命的损失。
从 2008 年至 2017 年,确定了因原发性 HF 住院的患者,并通过与死亡登记处的链接评估了全因死亡率。使用灵活的参数生存模型来估计生存情况、生存预测因素和预期寿命损失。共纳入 283048 例 HF 患者(平均年龄 78.2±12.3 岁,50.8%为男性)。其中,3 年内 48.3%(48.1-48.5)存活,5 年内 34.1%(33.9-34.3)存活,10 年内 17.1%(16.8-17.4)存活(中位生存时间为 2.8 年)。随着年龄的增长,生存率下降,18-54 岁的患者中有 53.4%,≥85 岁的患者中有 6.2%在 10 年内存活(≥85 岁与 18-54 岁相比,死亡率的调整后危险比[aHR]为 4.84,95%置信区间[CI]为 4.65-5.04),男性患者的情况更差(aHR 为 1.14,95%CI 为 1.13-1.15)。既往 HF(aHR 为 1.20,95%CI 为 1.18-1.22)、瓣膜性和风湿性心脏病(aHR 为 1.11,95%CI 为 1.10-1.13)和血管疾病(aHR 为 1.07,95%CI 为 1.04-1.09)是与长期死亡最密切相关的心血管合并症。非心血管合并症和老年综合征很常见,并与更高的死亡率相关。与普通人群相比,HF 导致预期寿命损失 7.3 年(或预期寿命的 56.6%),对于 18-54 岁的人群,这一数字达到 20.5 年。
不到五分之一的 HF 住院患者在 10 年内存活,与普通人群相比,这些患者的预期寿命损失近 60%,突出了 HF 持续存在的巨大社会负担。需要多学科协同努力,改善 HF 患者的出院后结局。